Dasselta 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued2 / 
affected3  
amended 
on 
PSUSA/962/ 
Periodic Safety Update EU Single assessment - 
24/03/2022 
30/05/2022 
SmPC and PL 
Please refer to Aerius-Azomyr-Neoclarityn-Desloratadine 
202107 
desloratadine 
Teva-Dasselta-Desloratadine Actavis-Desloratadine 
ratiopharm-EMEA/H/C/PSUSA/00000962/202107 EPAR: 
Scientific conclusions and grounds recommending the 
variation to the terms of the marketing authorisation 
IA/0020/G 
This was an application for a group of variations. 
05/10/2021 
n/a 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
 
 
 
 
 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
B.I.c.1.a - Change in immediate packaging of the AS 
- Qualitative and/or quantitative composition 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
N/0019 
Minor change in labelling or package leaflet not 
17/05/2021 
30/05/2022 
PL 
connected with the SPC (Art. 61.3 Notification) 
IB/0018 
C.I.2.a - Change in the SPC, Labelling or PL of a 
07/05/2020 
30/04/2021 
SmPC, Annex 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
II, Labelling 
and PL 
IB/0017 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
12/03/2018 
07/02/2019 
SmPC 
life of the finished product - As packaged for sale 
(supported by real time data) 
IB/0016 
C.I.z - Changes (Safety/Efficacy) of Human and 
07/02/2018 
07/02/2019 
SmPC, 
Veterinary Medicinal Products - Other variation 
Labelling and 
PL 
PSUSA/962/2
Periodic Safety Update EU Single assessment - 
23/03/2017 
18/05/2017 
SmPC and PL 
Refer to Scientific conclusions and grounds recommending 
01607 
desloratadine 
the variation to terms of the Marketing Authorisation(s)’ for 
Page 2/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IA/0015/G 
This was an application for a group of variations. 
05/04/2017 
n/a 
PSUSA/962/201607. 
A.7 - Administrative change - Deletion of 
manufacturing sites 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
IAIN/0014 
B.III.2.a.1 - Change of specification(s) of a former 
15/03/2017 
n/a 
non EU Pharmacopoeial substance to fully comply 
with the Ph. Eur. or with a national pharmacopoeia of 
a Member State - AS 
R/0012 
Renewal of the marketing authorisation. 
23/06/2016 
16/08/2016 
SmPC, Annex 
Based on the review of data on quality, safety and efficacy, 
II, Labelling 
the CHMP considered that the benefit-risk balance of 
and PL 
Dasselta in the approved indication remains favourable and 
therefore recommended the renewal of the marketing 
authorisation with unlimited validity. 
IA/0010 
B.II.b.4.a - Change in the batch size (including batch 
15/02/2016 
n/a 
size ranges) of the finished product - Up to 10-fold 
compared to the originally approved batch size 
IA/0011 
A.7 - Administrative change - Deletion of 
12/02/2016 
n/a 
manufacturing sites 
Page 3/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0009 
C.I.2.a - Change in the SPC, Labelling or PL of a 
07/10/2015 
21/04/2016 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0008 
C.I.2.a - Change in the SPC, Labelling or PL of a 
11/06/2015 
21/04/2016 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0007/G 
This was an application for a group of variations. 
28/04/2015 
21/04/2016 
SmPC and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0005/G 
This was an application for a group of variations. 
05/03/2015 
n/a 
Page 4/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.I.a.3.a - Change in batch size (including batch size 
ranges) of AS or intermediate - Up to 10-fold 
increase compared to the originally approved batch 
size 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
IAIN/0006 
C.I.8.a - Introduction of or changes to a summary of 
26/02/2015 
n/a 
Pharmacovigilance system - Changes in QPPV 
(including contact details) and/or changes in the 
PSMF location 
IB/0004 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
12/09/2013 
22/08/2014 
SmPC, Annex 
life of the finished product - As packaged for sale 
(supported by real time data) 
II, Labelling 
and PL 
N/0003 
Update of the local representatives contact details in 
02/07/2013 
22/08/2014 
PL 
Update of the local representatives contact details in the 
the package leaflet and inclusion of an additional 
local representative of the Marketing Authorisation 
Holder for the new Croatian Member State. 
Minor change in labelling or package leaflet not 
connected with the SPC (Art. 61.3 Notification) 
IA/0002 
A.4 - Administrative change - Change in the name 
22/10/2012 
n/a 
and/or address of a manufacturer or supplier of the 
AS, starting material, reagent or intermediate used 
in the manufacture of the AS 
package leaflet and inclusion of an additional local 
representative of the Marketing Authorisation Holder for the 
new Croatian Member State. 
Page 5/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N/0001 
Updated local representative contact details for 
13/03/2012 
22/08/2014 
Labelling and 
Ireland, Malta and Spain. The MAH also made 
editorial changes in the Bulgarian, Spanish and 
French package leaflets and for the labelling in 
Denmark. 
Minor change in labelling or package leaflet not 
connected with the SPC (Art. 61.3 Notification) 
PL 
Page 6/6 
 
 
 
 
 
 
 
 
 
 
